Managers / Q2 2023 · view latest →
Nextech Invest Ltd.
CIK 0001911010 · BAHNHOFSTRASSE 18, ZURICH, V8, CH-8001 · 41 (0)44 366 66 11
Summary
Nextech Invest Ltd. reported $294M in U.S.-listed holdings across 13 positions for Q2 2023.
The portfolio is heavily concentrated: RVMD alone accounts for 44.0% of reported value.
Compared with Q1 2023, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 89.8% · $264M
- Other · 10.2% · $30M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ORICORIC PHARMACEUTICALS INC | NEW | +4.29M | 4.29M | +$33M | $33M |
| RLAYRELAY THERAPEUTICS INC | ADDED | +323.2K | 948.7K | +$2M | $12M |
| PMVPPMV PHARMACEUTICALS INC | TRIMMED | −50.0K | 471.3K | +$463,713 | $3M |
| RVMDREVOLUTION MEDICINES INC | HELD | +0 | 4.84M | +$25M | $129M |
| KNTEUSDKINNATE BIOPHARMA INC | HELD | +0 | 2.33M | −$8M | $7M |
| TYRATYRA BIOSCIENCES INC | HELD | +0 | 2.52M | +$2M | $43M |
| EQRX INC | HELD | +0 | 13.10M | −$1M | $24M |
| ARVNARVINAS INC | HELD | +0 | 287.3K | −$718,127 | $7M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INChistory → | COM | 44.00% | $129M | 4.84M |
| 2 | TYRATYRA BIOSCIENCES INChistory → | COM | 14.58% | $43M | 2.52M |
| 3 | ORICORIC PHARMACEUTICALS INChistory → | COM | 11.30% | $33M | 4.29M |
| 4 | EQRX INC | COM | 8.28% | $24M | 13.10M |
| 5 | CGEMCULLINAN ONCOLOGY INChistory → | COM | 4.47% | $13M | 1.22M |
| 6 | SPRYARS PHARMACEUTICALS INChistory → | COM | 4.35% | $13M | 1.91M |
| 7 | RLAYRELAY THERAPEUTICS INChistory → | COM | 4.05% | $12M | 948.7K |
| 8 | ARVNARVINAS INChistory → | COM | 2.42% | $7M | 287.3K |
| 9 | KNTEUSDKINNATE BIOPHARMA INChistory → | COM | 2.40% | $7M | 2.33M |
| 10 | THESEUS PHARMACEUTICALS INC | COM | 1.94% | $6M | 611.3K |
| 11 | PMVPPMV PHARMACEUTICALS INChistory → | COM | 1.00% | $3M | 471.3K |
| 12 | KRON1USDKRONOS BIO INC | COM | 0.85% | $2M | 1.45M |
| 13 | CCCCC4 THERAPEUTICS INC | COM STK | 0.35% | $1M | 375.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $616M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $712M | 15 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $594M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $631M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $537M | 11 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $330M | 14 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $294M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $240M | 12 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $251M | 14 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $310M | 14 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $296M | 14 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $350M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $430M | 11 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.